ClinicalTrials.gg
CompletedNCT01094158Aramchol003Updated Jan 31, 2012

Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis

A Phase 2 interventional study of Aramchol and Aramchol in Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Metabolic Syndrome, sponsored by Galmed Medical Reserch. Completed at 11 sites in Israel. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-01-31.

Sponsored by Galmed Medical Reserch · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Non-alcoholic Fatty Liver Disease with a site in Israel — 6 open to participants now, 10 under way, 8 of them phase 3. Non-alcoholic Fatty Liver Disease · Israel.

Planned enrollment
32nd of 52
60 · median 111
Started
2010
with 4 others
Phase 2
20 of 63
1 open now
Registered
6th of 63
by date

Among the 63 studies in Non-alcoholic Fatty Liver Disease with a site in Israel, this one is the 32nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2010, is one of 20 in phase 2, and was the 6th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

6 of the 63 studies in Non-alcoholic Fatty Liver Disease with a site in Israel are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Non-alcoholic Fatty Liver Disease with a site in Israel, or all of them as a file.
02

Study summary

Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment.

Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.

Read the detailed description

A Phase II, multicenter, double blind, randomized, placebo controlled study on the effect of Aramchol on liver triglycerides concentration in patients with steatosis due to NAFLD or NASH

The purpose of the study is to test whether Aramchol will reduce safely and effectively liver fat concentration in patients with NAFLD and NASH.

Aramchol inhibits the liver enzyme Stearoyl Coenzyme A Desaturase (SCD). It reduces fatty acid synthesis while increasing fatty acid oxidation. It was shown to reduce liver fat in animal models with diet induced Fatty Liver. It has also marked hypocholesterolemic effects, mainly via upregulation of theABCA1 cholesterol transporter. It thus causes(incomplete) SCD inhibition while being antiatherogenic

Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment.

Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis
  • Metabolic Syndrome

Keywords

  • NAFLD
  • NASH
  • Fatty Liver
  • Metabolic Syndrome
  • Endothelial Dysfunction
  • Insulin Resistance
  • Liver Fat
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven NAFLD or NASH based on a performed during the preceding 18 months fulfilling the following criteria:

    • At least 15% of hepatocytes showing steatosis,with Fibrosis of not more than stage 3, with at most bridging fibrosis.

Patients with a NAFLD activity score 0-2 will be considered to have NAFLD. Biopsies with an activity score of 3 or more will be considered NASH.

  • Triglycerides concentration in the liver of 6% or more as measured by NMRS.
  • At least two elevated serum levels in the previous six months, with latest test within 2 months of trial.
  • Normal or only slightly impaired synthetic liver function (serum albumin >3.5gm%, 0.8-1.3)
  • Male or female aged 18-75 years.
  • Negative pregnancy test at study entry for females of child bearing potential.
  • Females of child bearing potential practicing reliable throughout the study period.
  • Signature of the written

Exclusion criteria

Exclusion Criteria:

  • Evidence of cirrhosis on liver .
  • Evidence of fibrosis of more than stage 3 on liver biopsy.
  • Patient with liver disease due to acute or chronic hepatitis A, B,C, , and all other liver diseases affecting liver function. Patients with cysts, hemangiomas, or similar abnormalities, are accepted.
  • > 35 or >130 kg body weight
  • Any other concomitant, significant: metabolic, infectious, inflammatory, neoplastic, or other non-liver disease.
  • Various concomitant diseases requiring chronic administration.
  • Use of warfarin, metformin, thiaglitazones, insulin or current steroid therapy of more than 3 days.
  • Use of other agents \< 30 days prior to the study.
  • Pregnancy
  • Daily alcohol intake > 10gm/day.
  • Patients with symptoms of significant mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give .
  • Performance status: ≥4.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    high dose

    Aramchol 300 mg daily (high dose)

    Drug: Aramchol

  • Experimental
    low dose

    100 mg daily (low dose)

    Drug: Aramchol

  • Placebo comparator
    Placebo

    Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.

    Drug: Placebo

Interventions

  • 100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months

    Also known as: Arachidyl amido cholanoic acid

  • 300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months

    Also known as: Arachidyl amido cholanoic acid

  • DrugPlacebo

    tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast

06

What researchers measure

Primary outcomes

  1. The difference between initial and final liver triglyceride concentration (measured by NMRS) comparing the Aramchol and placebo treated patients.

    Time frame: 3 months

Secondary outcomes

  1. Comparing secondary variables of liver, metabolic and endothelial functions between the Aramchol and the placebo arms.

    Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms

    Time frame: 3 months

07

Study locations

11 sites
  • Soroka Medical Center
    Beer Sheva, 84101, Israel
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Rambam
    Haifa, 31096, Israel
  • The Lady Davis Carmel Medical Center
    Haifa, 34362, Israel
  • Hadassah Ein Kerem M.C
    Jerusalem, 91120, Israel
  • Meir Medical Center
    Kfar Saba, 44281, Israel
  • Holy Family HOSPITAL
    Nazareth, Israel
  • Belinson,Rabin Medical Center
    Petah Tikva, 49100, Israel
  • Kaplan M.C
    Rehovot, 76100, Israel
  • Safed Ziv Hospital
    Safed, 13100, Israel
  • The Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
08

References and documents

Publications

  • Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, Bernheim J, Konikoff FM, Gilat T. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1205-13. doi: 10.1097/MEG.0b013e3282fc9743. PubMed 18989145 ↗
  • Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D, Konikoff FM. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology. 2003 Aug;38(2):436-42. doi: 10.1053/jhep.2003.50348. PubMed 12883488 ↗
  • Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1. doi: 10.1016/j.cgh.2014.04.038. Epub 2014 May 9. PubMed 24815326 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2010
First posted
Mar 26, 2010
Start
Nov 2010
Primary completionActual
Nov 2011
CompletionActual
Jan 2012
Last update
Jan 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01094158
Lead sponsor
Galmed Medical Reserch
Collaborators
Tel-Aviv Sourasky Medical Center, Beilinson Hospital, Petach Tikva,Israel, Meir Medical Center, Kaplan Hospital ,Rehovot,Israel, Soroka Hospital,Beer Sheva,Israel, Hadassah Medical Organization, Hillel Yaffe Medical Center, Rambam Hospital, Haifa, Israel, The Lady Davis Carmel Medical Center, Holy Family Hospital, Nazareth, Israel, Ziv Hospital
First posted
Mar 26, 2010
Start date
Nov 2010
Primary completion
Nov 2011
Completion
Jan 2012
Last update
Jan 31, 2012

Study contacts

Ran Oren, Doctor
principal investigator · Liver & Gastroenterology Department,The Tel Aviv Sourasky Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion